ZA201302362B - 4-(5-cyano-pyrazol-1-yl)-piperidine derivatives as gpr 119 modulators - Google Patents

4-(5-cyano-pyrazol-1-yl)-piperidine derivatives as gpr 119 modulators

Info

Publication number: ZA201302362B
Authority: ZA; South Africa
Prior art keywords: gpr; pyrazol; modulators; cyano; piperidine derivatives
Prior art date: 2010-11-23

Application number

ZA2013/02362A

Inventor

Vincent Mascitti

Kim Francis Mcclure

Michael John Munchhof

Ralph Pelton Robinson Jr

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-11-23

Filing date

2013-04-02

Publication date

2014-06-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45418722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201302362(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-04-02 Application filed by Pfizer filed Critical Pfizer

2014-06-25 Publication of ZA201302362B publication Critical patent/ZA201302362B/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Cardiology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Heart & Thoracic Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Hematology (AREA)
Endocrinology (AREA)
Ophthalmology & Optometry (AREA)
Obesity (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Urology & Nephrology (AREA)
Reproductive Health (AREA)
Emergency Medicine (AREA)
Dermatology (AREA)
Immunology (AREA)
Gynecology & Obstetrics (AREA)
Child & Adolescent Psychology (AREA)
Vascular Medicine (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

ZA2013/02362A 2010-11-23 2013-04-02 4-(5-cyano-pyrazol-1-yl)-piperidine derivatives as gpr 119 modulators ZA201302362B (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US41644110P	2010-11-23	2010-11-23
PCT/IB2011/054996 WO2012069948A1 (en)	2010-11-23	2011-11-09	4- (5-cyano-pyrazol-1-yl) -piperidine derivatives as gpr 119 modulators

Publications (1)

Publication Number	Publication Date
ZA201302362B true ZA201302362B (en)	2014-06-25

Family

ID=45418722

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA2013/02362A ZA201302362B (en)	2010-11-23	2013-04-02	4-(5-cyano-pyrazol-1-yl)-piperidine derivatives as gpr 119 modulators

Country Status (27)

Country	Link
EP (1)	EP2643310A1 (en)
JP (1)	JP2013543885A (en)
KR (1)	KR20130083915A (en)
CN (1)	CN103298801A (en)
AP (1)	AP2013006809A0 (en)
AR (1)	AR088121A1 (en)
AU (1)	AU2011333427A1 (en)
BR (1)	BR112013011865A2 (en)
CA (1)	CA2814231A1 (en)
CL (1)	CL2013001054A1 (en)
CO (1)	CO6801716A2 (en)
CR (1)	CR20130139A (en)
CU (1)	CU20130059A7 (en)
DO (1)	DOP2013000102A (en)
EA (1)	EA201370118A1 (en)
EC (1)	ECSP13012630A (en)
GT (1)	GT201300135A (en)
MA (1)	MA34805B1 (en)
MX (1)	MX2013004083A (en)
NI (1)	NI201300044A (en)
PE (1)	PE20140409A1 (en)
PH (1)	PH12013500677A1 (en)
SG (1)	SG189830A1 (en)
TW (1)	TWI433843B (en)
UY (1)	UY33742A (en)
WO (1)	WO2012069948A1 (en)
ZA (1)	ZA201302362B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR101913619B1 (en)	2011-06-09	2018-12-28	리젠 파마슈티컬스 소시에떼 아노님	Novel compounds as modulators of gpr-119
EP2872127A1 (en)	2012-07-11	2015-05-20	Elcelyx Therapeutics, Inc.	Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
JP2017119628A (en) *	2014-05-09	2017-07-06	日産化学工業株式会社	Substituted azole compound and therapeutic agent for diabetes
CN104610151A (en) *	2015-02-13	2015-05-13	佛山市赛维斯医药科技有限公司	Compound containing hydrazide and alkoxy benzene structures as well as preparation method and application thereof
CN104892517A (en) *	2015-02-13	2015-09-09	佛山市赛维斯医药科技有限公司	Hydrazine compound, method for preparing same and application of hydrazine compound
CN104592120A (en) *	2015-02-13	2015-05-06	佛山市赛维斯医药科技有限公司	Cyclopropyl hydrazide and methoxybenzene-containing GPR119 agonist as well as preparation method and application thereof
WO2017140771A1 (en)	2016-02-18	2017-08-24	Syngenta Participations Ag	Pesticidally active pyrazole derivatives
CN106631992B (en) *	2017-01-05	2019-01-18	桑迪亚医药技术（上海）有限责任公司	A kind of synthetic method of 4- oxygen -3,4- dihydro -2H- pyridine -1- t-butyl formate
CN115925702B (en) *	2022-12-14	2025-04-25	江西凌富生物科技有限公司	A purification method of imidazo[4,5-C]pyridine derivatives and imidazo[4,5-C]pyridine derivatives

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20100033419A (en) *	2007-07-19	2010-03-29	메타볼렉스, 인코포레이티드	N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the rup3 or gpr119 receptor for the treatment of diabetes and metabolic disorders
CL2009000782A1 (en) *	2008-03-31	2010-04-30	Metabolex Inc	Method comprising a substituted oxymethylene aryl derivative compound, dpp-iv inhibitors; and its use in the treatment of diabetes and lowering of triglycerides, among other diseases.
JP2012528847A (en) *	2009-06-05	2012-11-15	ファイザー・インク	L- (piperidin-4-yl) -pyrazole derivatives as GPR119 modulators

2011
- 2011-11-09 BR BR112013011865A patent/BR112013011865A2/en not_active IP Right Cessation
- 2011-11-09 CN CN2011800550665A patent/CN103298801A/en active Pending
- 2011-11-09 PH PH1/2013/500677A patent/PH12013500677A1/en unknown
- 2011-11-09 AU AU2011333427A patent/AU2011333427A1/en not_active Abandoned
- 2011-11-09 WO PCT/IB2011/054996 patent/WO2012069948A1/en active Application Filing
- 2011-11-09 CA CA2814231A patent/CA2814231A1/en not_active Abandoned
- 2011-11-09 PE PE2013001058A patent/PE20140409A1/en not_active Application Discontinuation
- 2011-11-09 MA MA35928A patent/MA34805B1/en unknown
- 2011-11-09 SG SG2013023189A patent/SG189830A1/en unknown
- 2011-11-09 MX MX2013004083A patent/MX2013004083A/en unknown
- 2011-11-09 EA EA201370118A patent/EA201370118A1/en unknown
- 2011-11-09 EP EP11802149.2A patent/EP2643310A1/en not_active Withdrawn
- 2011-11-09 JP JP2013540458A patent/JP2013543885A/en active Pending
- 2011-11-09 AP AP2013006809A patent/AP2013006809A0/en unknown
- 2011-11-09 KR KR1020137013064A patent/KR20130083915A/en not_active Ceased
- 2011-11-21 UY UY0001033742A patent/UY33742A/en unknown
- 2011-11-22 AR ARP110104351A patent/AR088121A1/en not_active Application Discontinuation
- 2011-11-22 TW TW100142804A patent/TWI433843B/en not_active IP Right Cessation
2013
- 2013-03-22 CR CR20130139A patent/CR20130139A/en unknown
- 2013-04-02 ZA ZA2013/02362A patent/ZA201302362B/en unknown
- 2013-04-16 CL CL2013001054A patent/CL2013001054A1/en unknown
- 2013-04-23 CU CU2013000059A patent/CU20130059A7/en unknown
- 2013-05-09 DO DO2013000102A patent/DOP2013000102A/en unknown
- 2013-05-13 NI NI201300044A patent/NI201300044A/en unknown
- 2013-05-20 EC ECSP13012630 patent/ECSP13012630A/en unknown
- 2013-05-21 GT GT201300135A patent/GT201300135A/en unknown
- 2013-05-23 CO CO13127143A patent/CO6801716A2/en not_active Application Discontinuation

Also Published As

Publication number	Publication date
AU2011333427A1 (en)	2013-04-11
PE20140409A1 (en)	2014-03-23
SG189830A1 (en)	2013-06-28
JP2013543885A (en)	2013-12-09
CN103298801A (en)	2013-09-11
ECSP13012630A (en)	2013-07-31
MX2013004083A (en)	2013-06-13
BR112013011865A2 (en)	2016-08-23
EA201370118A1 (en)	2013-12-30
MA34805B1 (en)	2014-01-02
CL2013001054A1 (en)	2013-09-27
EP2643310A1 (en)	2013-10-02
CA2814231A1 (en)	2012-05-31
DOP2013000102A (en)	2013-07-15
TWI433843B (en)	2014-04-11
NI201300044A (en)	2013-08-01
AR088121A1 (en)	2014-05-14
CO6801716A2 (en)	2013-11-29
CU20130059A7 (en)	2013-06-28
TW201300373A (en)	2013-01-01
GT201300135A (en)	2015-02-19
WO2012069948A1 (en)	2012-05-31
AP2013006809A0 (en)	2013-04-30
KR20130083915A (en)	2013-07-23
UY33742A (en)	2012-06-29
PH12013500677A1 (en)	2013-05-06
CR20130139A (en)	2013-06-28

Publication	Publication Date	Title
LT2536710T (en)	2016-09-26	Piperidine derivatives
ZA201302362B (en)	2014-06-25	4-(5-cyano-pyrazol-1-yl)-piperidine derivatives as gpr 119 modulators
ZA201107444B (en)	2012-06-27	Substituted 2-mercaptoquinoline-3-carboxamides as kcnq2/3 modulators
IL225762A0 (en)	2013-06-27	Substituted 6-amino-nicotinamides as kcnq2/3 modulators
ZA201209483B (en)	2014-02-26	Sunscreen composition
IL221959A (en)	2016-11-30	Propynylaminoindan transdermal compositions
ZA201107443B (en)	2012-07-25	Substituted 2-mercapto-3-aminopyridines as kcnq2/3 modulators
IL214944A0 (en)	2011-11-30	Substituted 3-amino-2-mercaptoquinolines as kcnq2/3 modulators
EP2548928A4 (en)	2013-09-18	PIGMENT COMPOSITION
ZA201302266B (en)	2016-02-24	Substituted 2-oxy-quinoline-3-carboxamides as kcnq2/3 modulators
ZA201206841B (en)	2014-03-26	Novel composition
ZA201302265B (en)	2021-05-26	Substituted 2-oxo-and 2-thioxo-dihydroquinoline-3-carboxamides as kcnq2/3 modulators
GB201011831D0 (en)	2010-09-01	New compounds 5
GB201009801D0 (en)	2010-07-21	Compounds 950
GB201000655D0 (en)	2010-03-03	New compounds 2
GB201012788D0 (en)	2010-09-15	Novel compounds 11
GB201012790D0 (en)	2010-09-15	Novel compounds 1
GB201021416D0 (en)	2011-01-26	Novel heterocyclic compounds
GB201009514D0 (en)	2010-07-21	Novel heterocyclic compounds
GB201102024D0 (en)	2011-03-23	Novel heterocyclic compounds 3
GB201101822D0 (en)	2011-03-16	Novel heterocyclic compounds 2
GB201101823D0 (en)	2011-03-16	Novel heterocyclic compounds 4
GB201101821D0 (en)	2011-03-16	Novel heterocyclic compounds 1
GB201201747D0 (en)	2012-03-14	Novel heterocyclic compounds 1
GB201201746D0 (en)	2012-03-14	Novel heterocyclic compounds 2